<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="140447">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01272596</url>
  </required_header>
  <id_info>
    <org_study_id>Sloan-Study</org_study_id>
    <nct_id>NCT01272596</nct_id>
  </id_info>
  <brief_title>Evaluation of Sloan-Charts for Assessment of Disease Progress in Multiple Sclerosis</brief_title>
  <official_title>Evaluation of Low Contrast Sloan Visual Charts as Method for the Assessment of Disease Progression in Multiple Sclerosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Charite University, Berlin, Germany</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Novartis Germany GmbH</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Charite University, Berlin, Germany</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Impairment of visual deficits, in particular contrast acuity and contrast impairment are
      frequent symptoms in MS. However, visual function is not appropriately covered by the
      standard tools for clinical assessment, namely, the EDSS and the MSFC.

      The primary aim of this study is to investigate, whether in MS patients contrast acuity and
      sensitivity change over a period of two years.

      Secondary aims are the correlation of visual contrast parameters with structural retinal
      changes and quality of life.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2009</start_date>
  <completion_date type="Actual">November 2013</completion_date>
  <primary_completion_date type="Actual">November 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Visual Contrast Acuity</measure>
    <time_frame>24 Months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Structural and Functional Changes of Optic Pathway</measure>
    <time_frame>24 Months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Neurological Assessment</measure>
    <time_frame>24 Months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life</measure>
    <time_frame>24 Months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Contrast Sensitivity</measure>
    <time_frame>24 Months</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">100</enrollment>
  <condition>Multiple Sclerosis</condition>
  <arm_group>
    <arm_group_label>Multiple Sclerosis Patients</arm_group_label>
    <description>Patients with Clinically Isolated Syndrome or definite Multiple Sclerosis (either relapsing-remitting or secondary progressive)</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with Clinically Isolated Syndrome or Definite Multiple Sclerosis
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Clinically Isolated Syndrome or definite MS (relapsing-remitting or secondary
             progressive course)

          -  Written Informed Consent

        Exclusion Criteria:

          -  Relapse within the last 30 Days

          -  Significant Cognitive Impairment

          -  Severely Decreased Visual Acuity

          -  Preexisting Severe Retinal Pathology
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jan M Dörr, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>NeuroCure Clinical Research Center, Charité Universitaetsmedizin Berlin</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>NeuroCure Clinical Reserach Center, Charité Universitaetsmedizin</name>
      <address>
        <city>Berlin</city>
        <zip>10117</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>November 2013</verification_date>
  <lastchanged_date>May 20, 2015</lastchanged_date>
  <firstreceived_date>January 7, 2011</firstreceived_date>
  <responsible_party>
    <name_title>Dr. Jan Dörr, MD</name_title>
    <organization>Charite University, Berlin, Germany</organization>
  </responsible_party>
  <keyword>Multiple Sclerosis</keyword>
  <keyword>Visual Contrast Acuity</keyword>
  <keyword>Visual Contrast Sensitivity</keyword>
  <keyword>Sloan Charts</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Sclerosis</mesh_term>
    <mesh_term>Multiple Sclerosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
